iTeos Therapeutics, Inc. (NASDAQ:ITOS) Expected to Post Earnings of $0.82 Per Share

Equities analysts predict that iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) will announce earnings of $0.82 per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for iTeos Therapeutics’ earnings. The lowest EPS estimate is $0.57 and the highest is $1.07. iTeos Therapeutics reported earnings per share of ($0.39) in the same quarter last year, which suggests a positive year-over-year growth rate of 310.3%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that iTeos Therapeutics will report full-year earnings of $3.39 per share for the current fiscal year, with EPS estimates ranging from $1.92 to $5.14. For the next year, analysts expect that the company will report earnings of ($0.84) per share, with EPS estimates ranging from ($6.59) to $2.36. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover iTeos Therapeutics.

Separately, Zacks Investment Research cut iTeos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 26th.

NASDAQ:ITOS traded down $1.04 during trading hours on Friday, reaching $26.69. 405,665 shares of the company were exchanged, compared to its average volume of 379,940. The stock’s 50-day moving average is $33.44 and its 200-day moving average is $35.06. The firm has a market cap of $947.76 million, a PE ratio of 4.77 and a beta of 1.91. iTeos Therapeutics has a twelve month low of $17.43 and a twelve month high of $52.43.

In other news, insider Joanne Jenkins Lager sold 3,500 shares of the company’s stock in a transaction on Friday, February 11th. The stock was sold at an average price of $35.85, for a total value of $125,475.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Michel Detheux sold 11,500 shares of the stock in a transaction dated Monday, April 18th. The stock was sold at an average price of $31.87, for a total value of $366,505.00. Following the transaction, the chief executive officer now owns 26,263 shares in the company, valued at $837,001.81. The disclosure for this sale can be found here. Insiders sold a total of 636,638 shares of company stock worth $22,389,373 over the last quarter. Company insiders own 3.95% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ITOS. Lindbrook Capital LLC purchased a new position in iTeos Therapeutics during the fourth quarter worth about $43,000. Royal Bank of Canada lifted its position in iTeos Therapeutics by 42.8% during the second quarter. Royal Bank of Canada now owns 2,474 shares of the company’s stock worth $63,000 after buying an additional 742 shares during the period. Nisa Investment Advisors LLC purchased a new position in iTeos Therapeutics during the fourth quarter worth about $95,000. Robeco Institutional Asset Management B.V. purchased a new position in iTeos Therapeutics during the first quarter worth about $97,000. Finally, Lazard Asset Management LLC purchased a new position in iTeos Therapeutics during the fourth quarter worth about $178,000.

About iTeos Therapeutics (Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Read More